Home › Funds › Cormorant Asset Management, LP › KLRA
Cormorant Asset Management, LP position in KLRA
KAILERA THERAPEUTICS INC · Health Care
Cormorant Asset Management, LP reported holding 400,000 shares of KLRA (KAILERA THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$4.6M, representing 0.33% of its reported portfolio and ranking #40 among its reported holdings. Cormorant Asset Management, LP has disclosed KLRA holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Cormorant Asset Management, LP's KLRA position evolved
Cormorant Asset Management, LP first disclosed a stake in KLRA in Q2 2026 at 550,000 shares (US$12.1M). Across 2 filings, Cormorant Asset Management, LP increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 400,000 shares valued at US$4.6M — a reduction of -150,000 shares quarter over quarter.. Notable position changes include a 27% trim in Q3 2026 (shares rose 10% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 550.00K | $12.12M | New |
| Q3 2026 | 400.00K | $4.57M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About KLRA and 13F data
KLRA (KAILERA THERAPEUTICS INC) is a Health Care company. 137 other funds we track also report a position in KLRA — the largest reported positions include BAIN CAPITAL INVESTORS LLC (US$299.8M), Bain Capital Life Sciences Investors, LLC (US$257.9M), RTW INVESTMENTS, LP (US$123.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding KLRA
- BAIN CAPITAL INVESTORS LLC 26.26M sh · $299.84M · Q3 2026
- Bain Capital Life Sciences Investors, LLC 22.58M sh · $257.90M · Q3 2026
- RTW INVESTMENTS, LP 10.78M sh · $123.07M · Q3 2026
- Atlas Venture Life Science Advisors, LLC 5.17M sh · $59.06M · Q3 2026
- Royalty Pharma Sub-Manager, LLC 2.46M sh · $28.04M · Q3 2026
- Siren, L.L.C. 2.21M sh · $25.29M · Q3 2026
- Farallon Capital Management 1.10M sh · $24.23M · Q2 2026
- Frazier Life Sciences Management, L.P. 1.20M sh · $13.70M · Q3 2026
- Trails Edge Capital Partners, LP 942.95K sh · $10.77M · Q3 2026
- Vestal Point Capital, LP 625.00K sh · $7.14M · Q3 2026
- Catalio Capital Management, LP 468.75K sh · $5.35M · Q3 2026
- a16z Capital Management, L.L.C. 140.00K sh · $1.60M · Q3 2026
More on Cormorant Asset Management, LP
FAQ
How long has Cormorant Asset Management, LP held KLRA?
Cormorant Asset Management, LP has disclosed KLRA holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is Cormorant Asset Management, LP's current position in KLRA?
As of Q3 2026, Cormorant Asset Management, LP holds 400.00K shares of KLRA (KAILERA THERAPEUTICS INC), valued at $4.57M, representing 0.33% of its reported portfolio and ranking #40.
Has Cormorant Asset Management, LP been buying or selling KLRA?
In the latest 13F filing (Q3 2026), Cormorant Asset Management, LP reduced its position in KLRA.
Which other funds hold KLRA?
Other major institutional holders of KLRA include BAIN CAPITAL INVESTORS LLC, Bain Capital Life Sciences Investors, LLC, RTW INVESTMENTS, LP, among 137 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.